Oruka Therapeutics (NASDAQ:ORKA) Hits New 1-Year Low – Here’s What Happened
Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) shares reached a new 52-week low during trading on Monday . The ...
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Average Rating of “Buy” from Brokerages
Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) have been given a consensus recommendation of “Buy” by the ...
Analysts Are Bullish on Top Healthcare Stocks: Oruka Therapeutics (ORKA), Vertex Pharmaceuticals (VRTX)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Oruka Therapeutics (ORKA – Research Report), ...
Oruka Therapeutics’s ORKA-001: Promising Psoriasis Treatment Drives Buy Rating with 12-Month Price Target of $45
H.C. Wainwright analyst Mitchell Kapoor has reiterated their bullish stance on ORKA stock, giving a Buy rating yesterday.Pick the best stocks ...
PipelineReview.com14d
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin diseases ...
Investing15d
Oruka Therapeutics enters exclusive licensing deal with Paragon
Oruka Therapeutics, Inc. (NASDAQ:ORKA), a biopharmaceutical company with a market capitalization of $753 million and strong financial health according to InvestingPro analysis, has entered into a ...
Investing15d
Oruka Therapeutics enters exclusive licensing deal with Paragon
Oruka Therapeutics, Inc. (NASDAQ:ORKA), a biopharmaceutical company with a market capitalization of $753 million and strong financial health according to InvestingPro analysis, has entered into a ...